← Back to Search

Diagnostic Test

Newborn infants born in North Carolina for Severe Combined Immunodeficiency

N/A
Waitlist Available
Led By Don Bailey, PhD
Research Sponsored by RTI International
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured within 6 months of participant screening results
Awards & highlights

Summary

Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and families who screen positive, and 3) evaluate the Early Check program. The Early Check screening will lead to earlier identification of newborns with rare health conditions in addition to providing important data on the implementation of this model program. Early diagnosis may result in health and development benefits for the newborns. Infants who have newborn screening in North Carolina will be eligible to participate, equating to over 120,000 eligible infants a year. Over 95% of participants are expected to screen negative. Newborns who screen positive and their parents are invited to additional research activities and services. Parents can enroll eligible newborns on the Early Check electronic Research Portal. Screening tests are conducted on residual blood from existing newborn screening dried blood spots. Confirmatory testing is provided free-of-charge for infants who screen positive, and carrier testing is provided to mothers of infants with fragile X. Affected newborns have a physical and developmental evaluation. Their parents have genetic counseling and are invited to participate in surveys and interviews. Ongoing evaluation of the program includes additional parent interviews.

Eligible Conditions
  • Severe Combined Immunodeficiency
  • Galactosemia
  • Long QT syndrome
  • ALD
  • Phenylketonuria
  • Wilson's Disease
  • Biotinidase Deficiency
  • Rett Syndrome
  • Pitt Hopkins Syndrome
  • Congenital Hyperinsulinism
  • Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome
  • Lysosomal Acid Lipase Deficiency
  • Pyridoxine-Dependent Epilepsy
  • Cerebrotendinous Xanthomatosis
  • Bile acid synthesis disorder
  • Dravet syndrome
  • Pancreatic agenesis
  • Hyperargininemia
  • Vitamin B12 Deficiency
  • Congenital hypothyroidism
  • Glycogen Storage Disease
  • Classical citrullinemia
  • Dravet Syndrome
  • MSUD
  • Diabetes Mellitus
  • Hemophilia B
  • Glycogen storage disease
  • Sudden Infant Death Syndrome
  • Fragile X Syndrome
  • Diabetes
  • Stickler Syndrome
  • Usher Syndrome
  • Acyl CoA Dehydrogenase Deficiency
  • Fructose Intolerance
  • Mitochondrial Protein Deficiency
  • Krabbe Disease
  • SCID
  • Hemophilia A
  • Serine deficiency
  • Neonatal Diabetes
  • Sickle Cell Disease
  • Gene Mutation
  • Beta-Ketothiolase Deficiency
  • Hypopituitarism
  • Molybdenum Cofactor Deficiency
  • Medium-chain acyl-CoA dehydrogenase deficiency
  • Fructose intolerance
  • Waardenburg Syndrome
  • Liddle syndrome
  • BRBGD
  • Deafness
  • Hyperinsulinism-Hyperammonemia Syndrome
  • Mildly elevated blood pressure
  • Erythrocyte pyruvate kinase deficiency
  • Holocarboxylase Synthetase Deficiency
  • Niemann-Pick Disease
  • Leber Congenital Amaurosis
  • Albinism
  • Hyperornithinemia-Hyperammonemia-Homocitrullinuria syndrome
  • Carnitine Translocase Deficiency
  • Acrodermatitis Enteropathica
  • Monoamine oxidase inhibitors
  • Dystonia
  • Mucopolysaccharidosis
  • Argininemia
  • Tuberous sclerosis
  • Hunter syndrome
  • Methylmalonic Acidemia
  • HMG-CoA lyase deficiency
  • Menkes Disease
  • Glut1 Deficiency Syndrome
  • Cori's Disease
  • Hypophosphatasia
  • Carnitine Palmitoyltransferase II Deficiency
  • Cystic Fibrosis
  • Citrullinemia
  • Post-Traumatic Stress Disorder
  • Canavan Disease
  • Glutaric Acidemia
  • Beta Thalassemia
  • Homocystinuria
  • Aortic Stenosis
  • RAG2 Deficiency
  • Transient Neonatal Diabetes Mellitus
  • Deaf-Blindness
  • Von Willebrand Disease
  • Congenital Hypothyroidism
  • Primary Hyperoxaluria
  • Alport Syndrome
  • Chronic Granulomatous Disease
  • Bubble Boy Disease
  • Congenital Adrenal Hyperplasia
  • Retinoblastoma
  • Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency
  • Cerebral Creatine Deficiency Syndrome
  • Pompe Disease
  • Wolcott-Rallison syndrome
  • Artemis Deficiency
  • Tyrosinemia
  • Liddle Syndrome
  • 3-Methylcrotonyl CoA Carboxylase 2 Deficiency
  • Rickets
  • Propionic Acidemia
  • Barth Syndrome
  • Adrenocorticotropic Hormone Deficiency
  • Creatine Transporter Deficiency
  • Friedreich's ataxia
  • Angelman Syndrome
  • Congenital Central Hypoventilation Syndrome
  • Riboflavin Transporter Deficiency
  • Vitamin B6-dependent epilepsy
  • Duchenne Muscular Dystrophy
  • Ornithine Transcarbamylase Deficiency
  • Metachromatic Leukodystrophy
  • 3-Methylcrotonyl CoA Carboxylase 1 Deficiency
  • Spinal Muscular Atrophy
  • Prader-Willi Syndrome
  • CPT1A Deficiency
  • High blood pressure
  • Glutathione synthetase deficiency
  • Argininosuccinic Aciduria
  • Branched-chain ketoacid dehydrogenase deficiency
  • Maroteaux-Lamy syndrome
  • Common Cold
  • Hurler syndrome
  • Isovaleric Acidemia
  • Cystinosis
  • Multiple Endocrine Neoplasia
  • Smith-Lemli-Opitz Syndrome
  • Hurler Syndrome
  • Pyridoxine-dependent epilepsy
  • CDG
  • Segawa Syndrome
  • Adenine Phosphoribosyl Transferase Deficiency
  • Tuberous Sclerosis
  • Pernicious Anemia
  • Morquio syndrome
  • G6PD Deficiency
  • Adrenal hyperplasia
  • Medium-Chain Acyl-CoA Dehydrogenase Deficiency
  • Neonatal hyperparathyroidism
  • Apparent Mineralocorticoid Excess
  • Hemophilia
  • N-acetylglutamate Synthase Deficiency
  • Diarrhea

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured within 6 months of participant screening results
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured within 6 months of participant screening results for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence Rates: Number of newborns who screen positive comparative to the whole sample
Secondary study objectives
Impact of Screening: Semi-structured parent interviews.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Newborn infants born in North CarolinaExperimental Treatment1 Intervention
All newborn infants in North Carolina will have the opportunity to participate in Early Check. Those who screen positive for the conditions identified in the study will be subject to confirmatory testing.
Group II: Birthing Mothers in North CarolinaExperimental Treatment0 Interventions
All birthing mothers in North Carolina will have the opportunity to participate in Early Check.

Find a Location

Who is running the clinical trial?

Illumina, Inc.Industry Sponsor
24 Previous Clinical Trials
124,456 Total Patients Enrolled
Janssen PharmaceuticalsIndustry Sponsor
82 Previous Clinical Trials
175,183 Total Patients Enrolled
GeneDxUNKNOWN
1 Previous Clinical Trials
100,000 Total Patients Enrolled
~822 spots leftby Nov 2024